[Role of transcutaneous radiotherapy in the treatment of pituitary adenoma].
D015065:17-Hydroxycorticosteroids / Q000378:metabolism; D015068:17-Ketosteroids / Q000378:metabolism; D000172:Acromegaly / Q000532:radiotherapy; D000239:Adenoma, Acidophil / Q000150:complications / Q000532:radiotherapy*; D000237:Adenoma, Basophil / Q000532:radiotherapy*; D000238:Adenoma, Chromophobe / Q000209:etiology / Q000532:radiotherapy*; D000328:Adult; D003480:Cushing Syndrome / Q000503:physiopathology / Q000532:radiotherapy*; D003920:Diabetes Mellitus / Q000209:etiology / Q000532:radiotherapy; D005260:Female; D005938:Glucocorticoids / Q000378:metabolism*; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D008297:Male; D008722:Methods; D010911:Pituitary Neoplasms / Q000150:complications / Q000532:radiotherapy*; D010912:Pituitary-Adrenal Function Tests; D011379:Prognosis; D011882:Radiotherapy, High-Energy; D014786:Vision Disorders / Q000209:etiology / Q000532:radiotherapy
D015065:17-Hydroxycorticosteroids; D015068:17-Ketosteroids; D005938:Glucocorticoids; D013006:Growth Hormone; D006854:Hydrocortisone
Place de la radiothérapie transcutanée dans le traitement des adénomes hypophysaires.